Nekrosis Tubular Akut
Published on September 6, 2026
Risk Factors
Prolonged hypotension (sepsis, hemorrhage, major surgery), nephrotoxin exposure (aminoglycosides, contrast dye, myoglobin, cisplatin), advanced age, pre-existing CKD, volume depletion, ICU admission
Etiology
Ischemic injury to renal tubular epithelial cells or direct nephrotoxic damage; the two most common causes of intrinsic acute kidney injury
Presentation
Oliguria or anuria developing after a hypotensive episode, major surgery, or nephrotoxin exposure; rising serum creatinine over days; may present with volume overload, uremic symptoms, or electrolyte derangements
Classic Exam
Often noncontributory in isolation; look for signs of the precipitating event (hypotension, sepsis stigmata, rhabdomyolysis with dark urine, recent IV contrast). Peripheral edema, pulmonary crackles if fluid overloaded
Diagnostics
Urinalysis: muddy brown granular casts and renal tubular epithelial cell casts. . Urine osmolality . Urine sodium . BUN:Creatinine ratio
Management
Supportive: IV fluids for volume optimization, removal of offending nephrotoxins, correction of electrolytes, dialysis if indicated (refractory hyperkalemia, severe metabolic acidosis, volume overload, uremic encephalopathy/pericarditis). Renal recovery expected in 1 to 3 weeks
Keywords
"Muddy brown casts," "post-operative oliguric renal failure," "rising creatinine after aminoglycoside use," "crush injury with dark urine," "contrast-induced nephropathy," "high FENa"
01Pathophysiology
ATN is the single most common cause of intrinsic acute kidney injury (AKI), and understanding it requires knowing two things: the anatomy of the renal tubule and the concept of a "watershed" blood supply.
The renal tubular epithelial cells, particularly those lining the proximal tubule and the thick ascending limb of the loop of Henle, are metabolically active cells that depend heavily on oxidative phosphorylation. These segments sit in the outer medulla, a zone that operates under physiologically low oxygen tension even under normal conditions. This makes the outer medulla exquisitely vulnerable to any further drop in perfusion. When systemic blood pressure falls (from hemorrhage, sepsis, or cardiac failure), renal blood flow decreases, and these segments are the first to suffer ischemic injury. This is why the classic exam scenario is a patient who develops oliguric AKI after a prolonged hypotensive episode or major surgery.
In the ischemic pathway, the injury progresses through a well-defined sequence. First, ATP depletion causes loss of cell polarity, meaning the -ATPase pumps redistribute from the basolateral membrane to the apical surface. This disrupts sodium reabsorption, which is why the kidney can no longer concentrate urine and why urinary sodium rises above 40 mEq/L and exceeds 2%. Damaged cells then slough off into the tubular lumen, forming the characteristic muddy brown granular casts that define ATN on urinalysis. These casts, along with cellular debris, obstruct the tubular lumen and cause a rise in intratubular pressure, which opposes glomerular filtration. Simultaneously, the disrupted tubular basement membrane allows filtrate to leak back into the interstitium ("backleak"), further reducing effective GFR.
In the nephrotoxic pathway, the mechanism is direct cellular toxicity rather than ischemia, but the downstream consequences are identical. Aminoglycosides accumulate in proximal tubular cells via megalin-mediated endocytosis and disrupt mitochondrial function. Contrast dye causes a combination of direct tubular toxicity and medullary vasoconstriction. Myoglobin (from rhabdomyolysis) and hemoglobin (from hemolysis) are freely filtered, precipitate in tubules in acidic conditions, and generate free radicals that damage epithelial cells. Cisplatin, another high-yield nephrotoxin, concentrates in the proximal tubule and causes DNA cross-linking and apoptosis.
The critical clinical concept is the three-phase model of ATN:
The initiation phase (hours to days) is the period of active injury. The insult is occurring, GFR is dropping, and this is the window where early intervention (restoring perfusion, discontinuing the offending agent) can limit damage.
The maintenance phase (1 to 2 weeks) is the oliguric or anuric period. Even after the insult is removed, the kidney remains non-functional because of tubular obstruction, backleak, and ongoing inflammation. Creatinine continues to rise, and this is when complications such as hyperkalemia, metabolic acidosis, and volume overload become dangerous.
The recovery phase begins when tubular cells regenerate. This phase is marked by a polyuric state because the newly regenerated tubular cells are not yet fully functional and cannot properly concentrate urine. During this phase, patients are at risk for volume depletion and electrolyte wasting (hypokalemia, hyponatremia, hypomagnesemia), and careful monitoring with fluid and electrolyte replacement is essential.
02Classification and Clinical Manifestation
By Etiology
Ischemic ATN
Mechanism
Sustained hypoperfusion causing tubular epithelial necrosis in the outer medulla
Common Causes
Hemorrhagic shock, septic shock, major cardiac or aortic surgery, severe dehydration, cardiogenic shock
Key Vignette Clues
"Blood pressure dropped to 70/40 during surgery," "prolonged ICU stay with vasopressor requirement," "massive GI bleed"
Nephrotoxic ATN
Mechanism
Direct chemical injury to tubular epithelial cells
Common Causes
Aminoglycosides (gentamicin, tobramycin), radiocontrast agents, cisplatin, amphotericin B, vancomycin (at supratherapeutic levels), tenofovir
Key Vignette Clues
"Started on gentamicin 5 days ago," "creatinine rise 48 to 72 hours after cardiac catheterization," "receiving cisplatin-based chemotherapy"
Pigment Nephropathy
Mechanism
Myoglobin or hemoglobin precipitation in tubules with free radical injury
Common Causes
Rhabdomyolysis (crush injury, statins, seizures, heat stroke), hemolytic transfusion reactions
Key Vignette Clues
"Found unconscious after earthquake," "dark brown urine," "markedly elevated CK," "recent blood transfusion with fever and flank pain"
Type | Mechanism | Common Causes | Key Vignette Clues |
|---|---|---|---|
Ischemic ATN | Sustained hypoperfusion causing tubular epithelial necrosis in the outer medulla | Hemorrhagic shock, septic shock, major cardiac or aortic surgery, severe dehydration, cardiogenic shock | "Blood pressure dropped to 70/40 during surgery," "prolonged ICU stay with vasopressor requirement," "massive GI bleed" |
Nephrotoxic ATN | Direct chemical injury to tubular epithelial cells | Aminoglycosides (gentamicin, tobramycin), radiocontrast agents, cisplatin, amphotericin B, vancomycin (at supratherapeutic levels), tenofovir | "Started on gentamicin 5 days ago," "creatinine rise 48 to 72 hours after cardiac catheterization," "receiving cisplatin-based chemotherapy" |
Pigment Nephropathy | Myoglobin or hemoglobin precipitation in tubules with free radical injury | Rhabdomyolysis (crush injury, statins, seizures, heat stroke), hemolytic transfusion reactions | "Found unconscious after earthquake," "dark brown urine," "markedly elevated CK," "recent blood transfusion with fever and flank pain" |
By Phase
Initiation
Duration
Hours to days
Clinical Features
Exposure to ischemia or nephrotoxin; urine output begins to fall; patient may still appear clinically stable
Laboratory Findings
Gradual rise in serum creatinine; urine sediment may initially be bland before casts appear
Maintenance (Oliguric)
Duration
1 to 2 weeks
Clinical Features
Oliguria () or anuria; volume overload (edema, pulmonary congestion); uremic symptoms (nausea, confusion, pericardial friction rub); electrolyte disturbances
Laboratory Findings
Peak serum creatinine; hyperkalemia, metabolic acidosis (elevated anion gap), hyperphosphatemia, hypocalcemia; muddy brown casts on urinalysis
Recovery (Polyuric)
Duration
Days to weeks
Clinical Features
Urine output increases dramatically (may exceed 3 to 5 L/day); patient improves clinically but is at risk for dehydration
Laboratory Findings
Creatinine begins to fall; risk of hypokalemia, hyponatremia, and hypomagnesemia due to tubular wasting
Phase | Duration | Clinical Features | Laboratory Findings |
|---|---|---|---|
Initiation | Hours to days | Exposure to ischemia or nephrotoxin; urine output begins to fall; patient may still appear clinically stable | Gradual rise in serum creatinine; urine sediment may initially be bland before casts appear |
Maintenance (Oliguric) | 1 to 2 weeks | Oliguria () or anuria; volume overload (edema, pulmonary congestion); uremic symptoms (nausea, confusion, pericardial friction rub); electrolyte disturbances | Peak serum creatinine; hyperkalemia, metabolic acidosis (elevated anion gap), hyperphosphatemia, hypocalcemia; muddy brown casts on urinalysis |
Recovery (Polyuric) | Days to weeks | Urine output increases dramatically (may exceed 3 to 5 L/day); patient improves clinically but is at risk for dehydration | Creatinine begins to fall; risk of hypokalemia, hyponatremia, and hypomagnesemia due to tubular wasting |
Non-oliguric ATN deserves attention because it is frequently tested. Some forms of nephrotoxic ATN (particularly aminoglycoside-induced) present with a rising creatinine but preserved urine output. This is a classic exam trap: students assume AKI always means oliguria. Non-oliguric ATN generally carries a better prognosis.
03Diagnostic Workup
Urinalysis with microscopy
Finding in ATN
Muddy brown granular casts, renal tubular epithelial cell casts
Purpose
Best initial test; hallmark finding that distinguishes ATN from prerenal azotemia
Fractional excretion of sodium ()
Finding in ATN
Purpose
Differentiates intrinsic renal disease from prerenal azotemia ()
Fractional excretion of urea ()
Finding in ATN
Purpose
Used when patient is on diuretics (which falsely elevate ); more reliable in this setting
Urine sodium
Finding in ATN
Purpose
Tubules cannot reabsorb sodium; contrasts with prerenal ()
Urine osmolality
Finding in ATN
Purpose
Tubules cannot concentrate urine; contrasts with prerenal ()
BUN:Creatinine ratio
Finding in ATN
Purpose
Both rise proportionally; in prerenal disease, BUN rises disproportionately ()
Serum creatinine
Finding in ATN
Rising trend over hours to days
Purpose
Confirms AKI; serial monitoring required
Basic metabolic panel
Finding in ATN
Hyperkalemia, metabolic acidosis, hyperphosphatemia, hypocalcemia
Purpose
Assesses complications of impaired renal function
Creatine kinase (CK)
Finding in ATN
Markedly elevated (, often )
Purpose
Ordered when rhabdomyolysis is suspected as the cause
Renal ultrasound
Finding in ATN
Normal-sized kidneys, no hydronephrosis
Purpose
Rules out obstructive (postrenal) causes
Renal biopsy
Finding in ATN
Tubular epithelial necrosis and regeneration
Purpose
Gold standard but rarely needed; reserved for atypical presentations where clinical diagnosis is uncertain
Test | Finding in ATN | Purpose |
|---|---|---|
Urinalysis with microscopy | Muddy brown granular casts, renal tubular epithelial cell casts | Best initial test; hallmark finding that distinguishes ATN from prerenal azotemia |
Fractional excretion of sodium () | Differentiates intrinsic renal disease from prerenal azotemia () | |
Fractional excretion of urea () | Used when patient is on diuretics (which falsely elevate ); more reliable in this setting | |
Urine sodium | Tubules cannot reabsorb sodium; contrasts with prerenal () | |
Urine osmolality | Tubules cannot concentrate urine; contrasts with prerenal () | |
BUN:Creatinine ratio | Both rise proportionally; in prerenal disease, BUN rises disproportionately () | |
Serum creatinine | Rising trend over hours to days | Confirms AKI; serial monitoring required |
Basic metabolic panel | Hyperkalemia, metabolic acidosis, hyperphosphatemia, hypocalcemia | Assesses complications of impaired renal function |
Creatine kinase (CK) | Markedly elevated (, often ) | Ordered when rhabdomyolysis is suspected as the cause |
Renal ultrasound | Normal-sized kidneys, no hydronephrosis | Rules out obstructive (postrenal) causes |
Renal biopsy | Tubular epithelial necrosis and regeneration | Gold standard but rarely needed; reserved for atypical presentations where clinical diagnosis is uncertain |
The workup for ATN is fundamentally an exercise in differential diagnosis. When you encounter a rising creatinine on an exam, the test-writer expects you to systematically categorize the AKI as prerenal, intrinsic, or postrenal before jumping to treatment.
Step 1: Rule out postrenal obstruction. Order a renal ultrasound. If bilateral hydronephrosis is present, the problem is obstructive, and the answer is catheterization or ureteral stent placement. This step is fast and easy, so it comes first.
Step 2: Distinguish prerenal from intrinsic. This is where the exam lives. The key formula is:
A suggests the tubules are working properly and avidly reabsorbing sodium in response to decreased perfusion (prerenal). A suggests the tubules are damaged and unable to reabsorb sodium (intrinsic, consistent with ATN). However, if the patient is on diuretics, becomes unreliable because diuretics artificially increase urinary sodium excretion. In this setting, use : a value suggests intrinsic disease.
Step 3: Examine the urine sediment. This is the single most discriminating test. Muddy brown granular casts are pathognomonic for ATN and will not appear in prerenal azotemia (which shows a bland sediment or hyaline casts). The vignette will often describe these casts, and that alone should clinch the diagnosis. Other urine sediment findings point to other intrinsic causes: RBC casts suggest glomerulonephritis, WBC casts suggest interstitial nephritis or pyelonephritis, and fatty casts (oval fat bodies) suggest nephrotic syndrome.
Step 4: Identify the precipitant. Once you have confirmed ATN, determine whether the cause is ischemic (look for preceding hypotension, surgery, sepsis), nephrotoxic (look for recent drug exposure), or pigment-related (look for crush injury, elevated CK, dark urine). This determines preventive strategy.
04Management and Treatment
Remove the offending agent
Intervention
Discontinue nephrotoxins
Details
Stop aminoglycosides, hold contrast dye, switch to less nephrotoxic alternatives; this is always the first step
Volume resuscitation (ischemic ATN)
Intervention
Isotonic saline (0.9% NaCl)
Details
Restore renal perfusion; target MAP ; avoid over-resuscitation once euvolemic
Rhabdomyolysis-induced ATN
Intervention
Aggressive IV normal saline
Details
Target urine output ; IV fluids at 1 to 1.5 L/hr initially; alkalinization of urine with IV sodium bicarbonate (target urine pH ) is sometimes used but remains debated
Contrast-induced ATN prevention
Intervention
Pre-procedure IV normal saline hydration
Details
1 mL/kg/hr for 6 to 12 hours before and 6 to 12 hours after contrast exposure; use low-osmolar or iso-osmolar contrast agents; hold metformin (risk of lactic acidosis with concurrent AKI)
Hyperkalemia
Intervention
Calcium gluconate, insulin + glucose, sodium bicarbonate, kayexalate, loop diuretics, or dialysis
Details
Calcium gluconate stabilizes the cardiac membrane (does not lower potassium); insulin drives potassium intracellularly; dialysis for refractory cases
Metabolic acidosis
Intervention
IV sodium bicarbonate if pH ; dialysis if refractory
Details
Correct severe acidemia; mild acidosis often resolves with restoration of renal function
Volume overload
Intervention
Loop diuretics (furosemide 40 to 80 mg IV) or dialysis
Details
Furosemide may convert oliguric to non-oliguric ATN (prognostically favorable) but does not change overall mortality or accelerate recovery
Dialysis indications
Intervention
Emergent hemodialysis
Details
Indicated for refractory hyperkalemia, severe metabolic acidosis (), refractory volume overload (pulmonary edema), uremic symptoms (encephalopathy, pericarditis, bleeding), and certain toxic ingestions
Recovery (polyuric) phase
Intervention
Monitor and replace fluids and electrolytes
Details
Watch for hypokalemia, hyponatremia, hypomagnesemia; replace IV fluids to match urine output; frequent electrolyte checks
Phase / Scenario | Intervention | Details |
|---|---|---|
Remove the offending agent | Discontinue nephrotoxins | Stop aminoglycosides, hold contrast dye, switch to less nephrotoxic alternatives; this is always the first step |
Volume resuscitation (ischemic ATN) | Isotonic saline (0.9% NaCl) | Restore renal perfusion; target MAP ; avoid over-resuscitation once euvolemic |
Rhabdomyolysis-induced ATN | Aggressive IV normal saline | Target urine output ; IV fluids at 1 to 1.5 L/hr initially; alkalinization of urine with IV sodium bicarbonate (target urine pH ) is sometimes used but remains debated |
Contrast-induced ATN prevention | Pre-procedure IV normal saline hydration | 1 mL/kg/hr for 6 to 12 hours before and 6 to 12 hours after contrast exposure; use low-osmolar or iso-osmolar contrast agents; hold metformin (risk of lactic acidosis with concurrent AKI) |
Hyperkalemia | Calcium gluconate, insulin + glucose, sodium bicarbonate, kayexalate, loop diuretics, or dialysis | Calcium gluconate stabilizes the cardiac membrane (does not lower potassium); insulin drives potassium intracellularly; dialysis for refractory cases |
Metabolic acidosis | IV sodium bicarbonate if pH ; dialysis if refractory | Correct severe acidemia; mild acidosis often resolves with restoration of renal function |
Volume overload | Loop diuretics (furosemide 40 to 80 mg IV) or dialysis | Furosemide may convert oliguric to non-oliguric ATN (prognostically favorable) but does not change overall mortality or accelerate recovery |
Dialysis indications | Emergent hemodialysis | Indicated for refractory hyperkalemia, severe metabolic acidosis (), refractory volume overload (pulmonary edema), uremic symptoms (encephalopathy, pericarditis, bleeding), and certain toxic ingestions |
Recovery (polyuric) phase | Monitor and replace fluids and electrolytes | Watch for hypokalemia, hyponatremia, hypomagnesemia; replace IV fluids to match urine output; frequent electrolyte checks |
The first principle of ATN management is that there is no pharmacologic therapy that reverses established ATN. The tubular epithelium must regenerate on its own, and supportive care is the cornerstone of treatment. This concept is tested frequently: dopamine, mannitol, and fenoldopam have all been studied and none have shown benefit. If an exam question offers "low-dose renal dopamine" as a treatment option for ATN, it is a distractor.
Step 1 is always to identify and remove the precipitant. If the patient is on an aminoglycoside, discontinue it. If hypotension caused the injury, restore perfusion with IV fluids and vasopressors as needed. If contrast dye was the trigger, ensure adequate hydration and avoid repeat exposure.
Step 2 is volume management. If the patient is hypovolemic (prerenal component contributing to ischemic ATN), isotonic crystalloid is the fluid of choice. If the patient is euvolemic or hypervolemic with pulmonary edema, loop diuretics or dialysis may be required. Furosemide is frequently tested: it can increase urine output and potentially convert oliguric ATN to non-oliguric ATN, which is associated with a better prognosis and easier fluid management. However, furosemide does not improve mortality or hasten tubular recovery, and it should not be used to "treat" ATN.
Step 3 is managing the complications of renal failure. Hyperkalemia is the most immediately life-threatening complication. The sequence is: (1) ECG to assess for peaked T waves, widened QRS, or sine wave pattern; (2) calcium gluconate if ECG changes are present (membrane stabilizer, buys time); (3) insulin (10 units regular IV) with dextrose (25 g IV) to shift potassium intracellularly; (4) definitive potassium removal via dialysis if refractory.
Step 4 is dialysis decision-making. The classic indications are remembered by the mnemonic AEIOU: Acidosis (refractory), Electrolyte abnormalities (refractory hyperkalemia), Ingestion (of dialyzable toxins), Overload (volume, refractory to diuretics), and Uremia (encephalopathy, pericarditis, bleeding diathesis). On an exam, if a patient with ATN develops any of these complications and medical management has failed, the next best step is hemodialysis.
For rhabdomyolysis-induced ATN, the key preventive and early treatment measure is aggressive IV fluid resuscitation with normal saline, targeting high-volume urine output. Urine alkalinization with sodium bicarbonate (goal urine pH ) is used at some centers to reduce myoglobin precipitation, but evidence remains mixed. Avoid lactated Ringer's in this setting because it contains potassium, and these patients are often already hyperkalemic from muscle breakdown.
For contrast-induced ATN prevention, the evidence-supported strategy is pre- and post-procedure IV normal saline hydration. N-acetylcysteine (NAC) was previously recommended but recent large trials (particularly the PRESERVE trial) showed no benefit, so it is no longer considered standard of care. If an exam offers NAC as the "best" preventive strategy, it is likely a distractor; IV saline hydration is the answer.
05Differential Diagnosis and Distractors
Prerenal azotemia
Why It Looks Similar
Rising creatinine, oliguria, occurs after hypotension or dehydration; identical clinical scenario to early ischemic ATN
Key Discriminator
, urine osmolality , bland urine sediment (hyaline casts or no casts), BUN:Cr . Creatinine improves rapidly with fluid resuscitation. ATN does not improve with fluids once established
Acute interstitial nephritis (AIN)
Why It Looks Similar
Drug-induced AKI with rising creatinine after starting a new medication; can mimic nephrotoxic ATN
Key Discriminator
Classic triad of fever, rash, and eosinophilia; urinalysis shows WBC casts and eosinophiluria (not muddy brown casts). Common culprits: NSAIDs, penicillins, cephalosporins, proton pump inhibitors, rifampin
Glomerulonephritis (GN)
Why It Looks Similar
Intrinsic AKI with abnormal urine sediment; both cause elevated creatinine and may present with oliguria
Key Discriminator
Urinalysis shows RBC casts and dysmorphic red blood cells (not muddy brown casts). Often accompanied by proteinuria, hypertension, and signs of a systemic disease (lupus, ANCA vasculitis, post-streptococcal infection)
Obstructive uropathy (postrenal AKI)
Why It Looks Similar
Rising creatinine with oliguria/anuria; may develop suddenly after surgery or in elderly patients with BPH
Key Discriminator
Bilateral hydronephrosis on renal ultrasound. History of BPH, pelvic malignancy, nephrolithiasis, or recent instrumentation. Creatinine improves after catheterization or stent placement
Hepatorenal syndrome (HRS)
Why It Looks Similar
Rising creatinine with low urine sodium and in a hospitalized patient, mimicking prerenal physiology
Key Discriminator
Occurs exclusively in the setting of advanced liver disease with portal hypertension (cirrhosis, ascites, jaundice). Does not respond to IV fluid challenge. Bland urine sediment. Treatment is albumin + vasopressors (midodrine + octreotide or terlipressin), not just fluids
Atheroembolic renal disease
Why It Looks Similar
AKI developing after a vascular procedure (catheterization, vascular surgery), mimicking contrast nephropathy
Key Discriminator
Onset is delayed (days to weeks after the procedure, not 24 to 72 hours). Physical exam shows blue/purple toes (livedo reticularis) despite palpable pulses. Labs show eosinophilia, low complement, elevated ESR. Urinalysis may show cholesterol clefts on biopsy
Thrombotic microangiopathy (TTP/HUS)
Why It Looks Similar
AKI with schistocytes and low platelets; may overlap with pigment nephropathy in terms of dark urine
Key Discriminator
Microangiopathic hemolytic anemia (schistocytes on smear, elevated LDH, low haptoglobin) with thrombocytopenia. Normal coagulation studies (PT/PTT). TTP features neurologic symptoms; HUS features diarrhea (often bloody, E. coli O157:H7)
Differential | Why It Looks Similar | Key Discriminator |
|---|---|---|
Prerenal azotemia | Rising creatinine, oliguria, occurs after hypotension or dehydration; identical clinical scenario to early ischemic ATN | , urine osmolality , bland urine sediment (hyaline casts or no casts), BUN:Cr . Creatinine improves rapidly with fluid resuscitation. ATN does not improve with fluids once established |
Acute interstitial nephritis (AIN) | Drug-induced AKI with rising creatinine after starting a new medication; can mimic nephrotoxic ATN | Classic triad of fever, rash, and eosinophilia; urinalysis shows WBC casts and eosinophiluria (not muddy brown casts). Common culprits: NSAIDs, penicillins, cephalosporins, proton pump inhibitors, rifampin |
Glomerulonephritis (GN) | Intrinsic AKI with abnormal urine sediment; both cause elevated creatinine and may present with oliguria | Urinalysis shows RBC casts and dysmorphic red blood cells (not muddy brown casts). Often accompanied by proteinuria, hypertension, and signs of a systemic disease (lupus, ANCA vasculitis, post-streptococcal infection) |
Obstructive uropathy (postrenal AKI) | Rising creatinine with oliguria/anuria; may develop suddenly after surgery or in elderly patients with BPH | Bilateral hydronephrosis on renal ultrasound. History of BPH, pelvic malignancy, nephrolithiasis, or recent instrumentation. Creatinine improves after catheterization or stent placement |
Hepatorenal syndrome (HRS) | Rising creatinine with low urine sodium and in a hospitalized patient, mimicking prerenal physiology | Occurs exclusively in the setting of advanced liver disease with portal hypertension (cirrhosis, ascites, jaundice). Does not respond to IV fluid challenge. Bland urine sediment. Treatment is albumin + vasopressors (midodrine + octreotide or terlipressin), not just fluids |
Atheroembolic renal disease | AKI developing after a vascular procedure (catheterization, vascular surgery), mimicking contrast nephropathy | Onset is delayed (days to weeks after the procedure, not 24 to 72 hours). Physical exam shows blue/purple toes (livedo reticularis) despite palpable pulses. Labs show eosinophilia, low complement, elevated ESR. Urinalysis may show cholesterol clefts on biopsy |
Thrombotic microangiopathy (TTP/HUS) | AKI with schistocytes and low platelets; may overlap with pigment nephropathy in terms of dark urine | Microangiopathic hemolytic anemia (schistocytes on smear, elevated LDH, low haptoglobin) with thrombocytopenia. Normal coagulation studies (PT/PTT). TTP features neurologic symptoms; HUS features diarrhea (often bloody, E. coli O157:H7) |
06Traps and High-Yield Pearls
The most common way students lose points on ATN questions is by confusing it with prerenal azotemia. Both conditions can follow hypotension, both cause oliguria, and both produce a rising creatinine. The entire diagnostic strategy hinges on the urine studies: prerenal azotemia shows concentrated urine with low sodium and a bland sediment (the tubules are working and compensating for low perfusion), while ATN shows dilute urine with high sodium and muddy brown casts (the tubules are damaged and unable to do their job). A vignette describing a post-surgical patient with oliguria and a rising creatinine is testing whether you can make this distinction. The answer to "what is the best next step?" is almost always to check urinalysis with microscopy and calculate .
A second common trap involves diuretic use confounding . If the patient is on furosemide or another loop diuretic, will be falsely elevated even in prerenal azotemia, because the diuretic blocks sodium reabsorption. In this scenario, the correct test is , which is not affected by diuretics. A confirms intrinsic renal disease; a suggests prerenal physiology. If you see a question where the is elevated but the patient is on diuretics, do not automatically call it ATN.
A third trap targets the recovery phase. Students focus on the oliguric phase and forget that the polyuric recovery phase carries its own dangers. When the question describes a patient with ATN whose creatinine is now trending down but who suddenly develops weakness, cardiac arrhythmias, or muscle cramps, the answer is hypokalemia from renal potassium wasting during the diuretic recovery phase. The correct management is aggressive potassium monitoring and replacement.
Finally, remember that contrast-induced nephropathy (a form of nephrotoxic ATN) has a predictable timeline: creatinine rises within 24 to 72 hours of contrast exposure and typically peaks at 3 to 5 days. If a vignette describes AKI occurring weeks after a catheterization with livedo reticularis and eosinophilia, that is atheroembolic disease, not contrast nephropathy. This timeline distinction is a favorite exam question.
The core competency being tested with ATN is your ability to correctly localize the cause of AKI (prerenal vs. intrinsic vs. postrenal), use urine studies to confirm the diagnosis, manage complications supportively, and recognize when dialysis is indicated.